[moreButton]
 Learn then Earn

 story : AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth .8 billion #FinanceUSA #StockMarketNEWS Shares of AbbVie Inc. were up 0.8% in premarket trading on Monday after

@stockMarketNEWS 12 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth .8 billion #FinanceUSA #StockMarketNEWS
Shares of AbbVie Inc. were up 0.8% in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and commercialize Regenxbio Inc.'s experimental gene therapy, which is being tested as a treatment for several eye diseases. Regenxbio's stock jumped 18.2% on the news. AbbVie will make an initial payment of 0 million, with additional potential milestone payments worth up to .4 billion. The deal is expected to close by the end of this year. So far this year, AbbVie's stock is down 0.4% and shares of Regenxbio have dropped 27.0%. The S&P 500 has gained 18.7%.


Munafa USA Munafa India Munafa NSE


Report

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme